37 results about "Translation initiation sites" patented technology

Compositions and methods are provided for the treatment and diagnosis of diseases associated with the expression of one or more of the betaI, betaII, gamma, delta, epsi, ζ or eta isoforms (isozymes) of protein kinase C (PKC). Oligonucleotides are provided which are targeted to nucleic acids encoding PKC-betaI, PKC-betaII, PKC-gamma, PKC-delta, PKC-epsi, PKC-ζ or PKC-eta. Provided herein are oligonucleotides specifically hybridizable with a translation initiation site, 5'-untranslated region, 3'-untranslated region or other targeted region of a betaI, betaII, gamma, delta, epsi, ζ or eta isoform of PKC, wherein at least about 75% of the nucleoside units of a given oligonucleotide are joined together by a stereospecific (i.e., Sp or Rp) phosphorothioate 3' to 5' linkages. In preferred embodiments, the oligonucleotides of the disclosure additionally contain one or more chemical modifications. Also disclosed are methods of using the oligonucleotides of the invention for modulating the expression of at least one of the betaI, betaII, gamma, delta, epsi, ζ or eta isoforms of PKC and for treating animals suffering from disease amenable to therapeutic intervention by modulating the expression of one or more of the betaI, betaII, gamma, delta, epsi, ζ or eta isoforms of PKC.

Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of the synthesis or metabolism of intercellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5'-untranslated sequences, 3'-untranslated sequences, and intervening sequences. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating cell adhesion proteins with an oligonucleotide specifically hybridizable with RNA or DNA corresponding to one of the foregoing proteins are disclosed. Methods for treatment of diseases responding to modulation cell adhesion molecules are disclosed.

The invention discloses an application of single nucleotide polymorphism rs3888188 to detection of tuberculosis susceptibility. The SNP (Single Nucleotide Polymorphism) is the rs3888188 and is positioned in a human IFITM3 (interferon induced transmembrane protein) gene core promoter region (namely the upstream 103bp of a transcription initiation site/the upstream 204bp of a translation initiation site ATG), the rs3888188G is a risk factor of tuberculosis susceptibility, and the polymorphism of the rs3888188 is highly related with tuberculosis. When the genotype of the site is GG, the tuberculosis susceptibility or tuberculosis causing risk of an individual to be detected is increased. The application is of significant meaning and value in the aspects of diagnosing and treating the tuberculosis to reasonably prevent the tuberculosis.

The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions related to certain promoter mutations in cancer. In one embodiment, a method for treating a subject having thyroid cancer comprises the steps of (a) obtaining a biological sample from the subject; (b) performing an assay on the sample obtained from the subject to identify a mutation at 1 295 228 C>T (C228T) and 1 295 250 C>T (C250T), corresponding to −124 C>T and −146 C>T from the translation start site in the promoter of the telomerase reverse transcriptase (TERT) gene; (c) identifying the subject as having or likely to develop aggressive thyroid cancer if the C228T and/or C250T mutation is identified; and (d) treating the subject with one or more treatment modalities appropriate for a subject having or likely to develop aggressive thyroid cancer.

The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions related to certain mutations in cancer. In one embodiment, a method for treating a subject having aggressive thyroid cancer comprises the steps of (a) obtaining a biological sample from the subject; (b) performing an assay on the sample obtained from the subject to identify a mutation at 1 295 228 C>T (C228T), corresponding to −124 C>T from the translation start site in the promoter of the telomerase reverse transcriptase (TERT) gene, and a T1799A mutation in the BRAF gene that results in a V600E amino acid change; (c) identifying the subject as having or likely to develop aggressive thyroid cancer if the C228T and V600E mutations are identified; and (d) treating the subject with one or more treatment modalities appropriate for a subject having or likely to develop aggressive thyroid cancer. Similar approaches are applied to other human cancers harboring both BRAF V600E mutation and TERT promoter mutations.

The present invention relates to a method and kit for identifying a translation initiation site on an mRNA. The method involves contacting a first mRNA with a first translation inhibitor to preferentially stabilize one or more initiation ribosomes at translation initiation sites on the first mRNA. A second mRNA is contacted with a second translation inhibitor different from the first translation inhibitor to stabilize one or more initiation ribosomes and one or more elongation ribosomes on the second mRNA. The location of ribosomes stabilized on the first mRNA is compared to the location of ribosomes stabilized on the second mRNA.

The invention discloses a method for detecting ox FTO (Fat Mass and Obesity-associated) gene single nucleotide polymorphism (SNP), which comprises the following steps of: carrying out PCR (Polymerase Chain Reaction) amplification on an ox FTO gene by adopting FTO gene-contained ox whole genome DNA to be detected as a template and a primer pair P as a primer; after carrying out high-temperature denaturation on a PCR product, carrying out polyacrylamide gel electrophoresis; and identifying the SNP of the 783rd site (+1 as a translation initiation site) of an ox FTO gene coding area according to a polyacrylamide gel electrophoresis result. Because the FTO gene function involves in body length and body height characters, the detecting method provided by the invention lays the foundation for establishing an SNP and growth character relation of the FTO gene so as to be used for marker-assisted selection (MAS) of growth characters for Chinese beef and rapidly establish an ox population with favorable genetic resources.

The invention discloses a rice large-grain gene function marker and application. The function marker is selected from one or more of a GS2 function marker, a GW2 function marker, a GL3.1 function marker and a GW2 promoter marker, wherein the GS2 function marker is a dCaps marker developed for TC/AA mutation of a third exon of a GS2 gene, the GW2 function marker is a dCaps marker developed for nucleotide A deletion mutation of a fifth exon of a GW2 gene, the GL3.1 function marker is a dCaps marker developed for single-base C/A mutation of a tenth exon of a GL3.1 gene, and the GW2 promoter marker is a dCaps marker developed for T/A mutation at upstream 858bp of a GW2 translation initiation site. The invention develops effective dCas markers for key variation sites of rice large-grain genes,can effectively identify large-grain rice germplasm and is applied to molecular breeding of rice.

The present invention constitutes three kinds of targeting vector capable of being located and integrated onto pig serum albumin locus and makes it possible to produce human serum albumin with pig serum. First, the 35 kb, including the 14 kb before translation starting site, all the exons and introns, and 3'-end translation 4 kb, of pig albumin genome are cloned and sequence analyzed. Then, two kinds of targeting vector capable of locating and integrating human serum albumin cDNA onto pig serum albumin and one kind of targeting vector capable of locating and integrating human serum albumin cDNA onto pig serum albumin locus are constituted. These targeting vectors are transfected pig fetus fibroblast or other cells, hitted cells are screened for nuclear transplantation of animal cells, and transgenic pig capable of producing human serum albumin in its serum is obtained.

Provided herein are methods of treating a cancer in a patient comprising administration of an effective amount of a nuclease-resistant polynucleotide that hybridizes to the translation initiation site of a Grb2 nucleic acid in the patient and either a Bcr-Abl tyrosine kinase inhibitor (e.g., dasatinib) or a cytidine analogue (e.g., decitabine or cytarabine). The cancer may be Ph+ and/or Bcr-Abl positive chronic myelogenous leukemia or acute myeloid leukemia or myelodysplastic syndrome.